I have had my doubts about the relationship between NP and

New Post Public Reply Private Reply Replies (1) Message Board
TechGuru
851
I have had my doubts about the relationship between NP and BP. Not sure what has transpired but I have "felt" NP a bit cold towards BP. In last conference call he mentioned that "we don't count on Dr. Patterson paper" or something similar. Don't remember the exact words.

Listening to Dr. Patterson interview yesterday it is obvious that he is fully in our side and remains the best Leronlimab advocate. So, I am not sure now that something has gone wrong as Dr. Paterson is talking as he was and is the biggest fan of CytyDyn.

His paper is coming !!!!! Below a transcript (from Dr. Yo's interview) where he explains what is going on:

What is going on with paper: Again I, I’m frustrated by the Journal it up the COVID endemic forcing people to publish preprints; because people who don’t understand the publication process know that it’s a relatively long process, is obvious accelerated in COVID and, and clearly you know, there was, there is several issues, I mean the main being no controls, right? and you know, these patients beyond critical and we are blessed that hum … some of the other coauthors and myself had great collaborators who stepped up the plate and said: listen I got some critical controls that haven’t been treated and let’s ad add those to the paper.
and then, you know, by the time we add those we had day 14th data which made everything even more powerful like I said this inverse correlation between CD8s coming back up and plasma viral load going down, absolutely critical, now people are coming out in reverse saying that is the CD8 deficiency ah, or the recovery of the CD8s ahmm that is eventually, you know, going to eliminate a virally infected cells. So then, we included CD 14th day and then, of course, it was outcomes: you know all 11 patients had incredible immunologic response the outcomes were good for this particular population, 8 out of eleven, or 7 out of 11 were transplant patients on top of everything else .. ah I just had not been addressed … So in fact, I checked on it today and it's, it's in process I think they are probably close to a decision, and then the journals when there is a decision will get it out in e-pub relatively quickly. But if you talk about the time from submission to going out in e-Pub in 3 months I mean, under normal circumstances, we would be popping the champagne bottle in how fast that is, right ??? some publications normally take 6, 12 months from the time they are actually submitted to the time they are out in print. so you know, I get the frustration, I’m just a frustrated at the pace, but you know what ? after publishing 150 papers, nothing, this is business as usual. Are the political things going behind the scenes? possibly ahh. But, in the day is gonna come out; I mean, the bottom line is: you don’t write a great paper and doesn’t get out anywhere is only matter of which journal gets it out there … at the end of the day, it does not matter, right??? if it is in a top tier Journal it's fine but it doesn't have to be, you know, solely New England Journal, Lancet, Nature, Science, you know, I published in all those before and yes, is a great honor but you know what ? they accept one in 100 papers so … yeah there’s other papers on Leronlimab that have undergone the same fate, so, we are in the same boat and I think the recurring theme is: lack of control patients and, obviously, that is going to come in the clinical trials and certainly in the IND’s we didn’t have controls, we didn’t have placebo controls, we went out and got them from our obviously some great collaborators of ours which made the trial much more than just, you know, just, looking at Leronlimab, we had to look at what was going on and repeat the entire assays that we did on the treated patients on the controls, so you can imagine the study size actually double, you know, in the course of, this being evaluated, so again, yeah there’s every reason in the world why, you know, it’s taking this long, but like I said, with, after 150 publications there is nothing that is unusual about this in the least


I can't wait to see the final paper, and more so, the "market" and scientific community reaction to it.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sunshine Silver Names Patterson to Boost Investor Ties

Updated Category News Views 3

Shifts in Silver Mining: A New Face at Sunshine Awright, let's talk silver. No, not paper dollars, but the shiny stuff in the ground. Sunshine Silver Mining & Refining's just brought a guy named Mike Patterson onboard to shake things up with investor relations and corporate strategy. Sunshine's got big plans, you see. They're eyeing the restart of the Sunshine Mine,...

Continue Reading
Exploring Denture to Implant Solutions with Dr. Miller

Updated Category News Views 0

The Changing Face of Tooth Replacement Let's dive into teeth. We're talking dentures, implants, and the rest of the gang that live in the world of full mouth replacements. Dr. Christopher Glenn Miller’s insights shared with HelloNation zero in on the evolution of tooth replacement options. Gone are the days of clunky dentures being your only shot. From sucking gum to...

Continue Reading
Midland Boosts Market Reach With Pegasus Acquisition

Updated Category News Views 1

A Strategic Leap In Connection Products You know, in the business world, it's all about making those smart moves that position you right at the doorstep of growth. Midland Industries is doing just that with its recent acquisition of Pegasus Supply Group. While Midland didn't spill the beans on the financials, this takeover seems more than just a simple grab for assets....

Continue Reading
Safety Tech in Fleets: Drivers Embrace Its Role

Updated Category News Views 0

Drivers Warming Up to Fleet Safety Tech Seems like most fleet drivers these days are eyeing safety tech through a fresher lens. Gone are the days when grumbling about privacy was the anthem of the disgruntled. The latest Linxup survey claims a whopping 77% of commercial fleet pros have hopped onto the safety train, happily trading privacy qualms for the perks of solid...

Continue Reading
Education's Future Explored at Reagan Institute Summit

Updated Category News Views 1

When Second Lady Usha Vance joins a summit, folks know it's a big deal. The Reagan Institute’s Education Summit is shaping up to be a showdown of ideas, tackling education’s role in a whirlwind of technological and political changes. This ain’t your average PTA meeting. We’re talking heavyweights like Utah Governor Spencer Cox and Colorado Governor Jared Polis...

Continue Reading
Tranter's New Press Boosts Vänersborg Operations

Updated Category News Views 1

Tranter's Bold Move in Manufacturing No smoke and mirrors about it—Tranter's pulling out the big guns in Vänersborg with a shiny new 5,000-metric-ton press. And why not? As heat exchangers become hotter commodities, you've got to gear up to meet the demand or watch customers drift. This isn't just a new toy; it's a weapon for dominating growing markets. Precision and...

Continue Reading
Immunic Paves Path with New Digital Leadership

Updated Category News Views 2

Shifting Gears: A Closer Look at Immunic's New Direction It's not every day you witness a biotech outfit like Immunic making waves with a high-profile leadership shift. Today, they introduced Chitrang Davé as their Chief Data and Digital Officer. Why's this a big deal? Well, it's a signal that Immunic is dead serious about stepping into commercial territory. The Role and...

Continue Reading
Adecoagro Expands with Caarapó Mill Acquisition

Updated Category News Views 0

Crushing the Competition: Adecoagro's New Acquisition When there's dirt under your fingernails and deals in the air, taking a strategic swing like Adecoagro just did can be a game-changer. Shelling out R$705 million (roughly US$136 million) in cash isn't what you'd call pocket change, but they're not new to ballsy moves. They've snapped up the Caarapó Mill, previously...

Continue Reading
Get Scared Early: First Fright 2026 Kicks Off!

Updated Category News Views 4

Gearing Up for Sneak-Attack Thrills Look, some folks stock up on candy by October, but the real adrenaline junkies? They’re already on the road long before that, eyes set on hitting America's creepiest haunts. This year, the game isn't just October. Mark the date—September 11 is when the screams start pushing the limits of your vocal cords, thanks to America Haunts....

Continue Reading
Ignyte Insurance Acquires InsureMyTrip to Expand Portfolio

Updated Category News Views 0

Key Acquisition: Strengthening Global Presence Ignyte Insurance just added a major player to its roster with the acquisition of InsureMyTrip. No two ways about it, this move is about expanding their footprint in the booming travel and medical insurance sector. Now, if you've ever thought travel insurance was just fine print nobody reads, think again. This industry’s got...

Continue Reading

Top 5 Most Recently Viewed Articles

VanillaSoft Welcomes New Leadership for Future Growth

Updated Category News Views 191

VanillaSoft Announces Key Leadership Changes Austin, Texas - VanillaSoft, a leading sales engagement technology company, has taken significant steps to enhance its leadership team. The recent appointments mark a strategic move aimed at driving the company’s growth and improving customer experiences. Paul McGee's Promotion to Senior Vice President In an exciting...

Continue Reading
Globe Life, Inc. Highlights Solid Financial Performance Q3 2024

Updated Category News Views 55

Globe Life Reports Impressive Q3 Financial Results Globe Life Inc. (NYSE: GL) recently announced its financial results for the third quarter of 2024, marking significant growth compared to the previous year. The company reported a net income of $3.44 per diluted common share, a notable increase from $2.68 per diluted share in the same quarter of the prior year....

Continue Reading
TechnoMile's Merger: The Future of Government Contractor Solutions

Updated Category News Views 178

TechnoMile’s Path to Growth: A Strategic Merger TechnoMile, an ambitious AI-powered platform for government contractors, has achieved remarkable growth over the years. This incredible journey took a significant leap forward with the recent merger with SIMS Software, a well-respected name in industrial security software. K1 Investment Management, a leading investor in...

Continue Reading
Rigel Pharmaceuticals Grants New Stock Options for Employees

Updated Category News Views 120

Rigel Pharmaceuticals Announces Employee Stock Options Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) has recently made headlines by granting new stock options to its employees, an action that reflects the company’s commitment to its workforce. This decision was made in alignment with NASDAQ Listing Rule 5635(c)(4), facilitating new employment compensations for the team at...

Continue Reading
Investigation of Applied Therapeutics: Investors Take Action

Updated Category News Views 208

Investigation into Applied Therapeutics, Inc. Recently, concerns have been raised regarding the performance and governance of Applied Therapeutics, Inc. (NASDAQ: APLT). Legal discussions have initiated an investigation focused on possible violations of federal securities laws, dedicated to protecting the interests of investors. Shocking Developments for Shareholders On...

Continue Reading